Analysis of response rate with anti-PD1/PDL1 antibodies in advanced solid tumors: A meta-analysis of randomized clinical trials (RCT).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14576
Abstract: e14576Background: Anti-PD1/PDL1 antibodies (mAbs) have been shown to increase overall survival (OS) compared to standard of care (SOC) in solid tumors (mainly melanoma and lung cancer). Despite the efficacy in OS, a significant proportion of… read more here.
Keywords: anti pd1; solid tumors; response; pd1 pdl1 ... See more keywords